News
Eli Lilly's acquisition of Vere Therapeutics promises to revolutionize cardiovascular care with innovative one-time gene ...
Eli Lilly and Company has acquired Verve Therapeutics Inc., a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.
Detailed price information for Verve Therapeutics Inc (VERV-Q) from The Globe and Mail including charting and trades.
A backlash against a White House video promoting deportation and Casalonga opening a new office in Düsseldorf were also among the top talking points ...
Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...
Verve Therapeutics, Inc. (NASDAQ:VERV) is one of the Stocks With Huge Catalysts on the Horizon. On April 14, Verve ...
Editas' share price has struggled due to clinical setbacks, but recent focus on in-vivo gene editing offers renewed hope and ...
The August 1 tariff deal is approaching; however, the market seems to have gotten used to the tariff headlines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results